Filing Analysis
Orchestra BioMed Holdings, Inc. held its 2026 Annual Meeting of Stockholders on June 23, 2026. The meeting resulted in the successful election of three Class III directors and the approval of several key shareholder proposals.
📋 Key Facts
- Annual Meeting held on June 23, 2026.
- Total shares entitled to vote: 59,880,715; Shares represented at meeting: 49,053,298.
- Elected David P. Hochman, Darren R. Sherman, and Eric S. Fain as Class III directors until the 2029 annual meeting.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- Approved the 2026 Equity Incentive Plan (ESPP Proposal).
- Stockholders approved executive compensation on an advisory basis and voted to maintain a '1 Year' frequency for say-on-pay votes.
Orchestra BioMed Holdings announced the adoption of a 2026 cash bonus plan for executive officers and updates to compensation structures. The plan is tied to clinical trial milestones (BACKBEAT and Virtue SAB) and financial objectives.
🚩 Red Flags
- Increased executive compensation (salaries and bonus percentages) during a period where clinical milestones are the primary driver of value.
📋 Key Facts
- Board approved the 2026 Cash Bonus Plan on February 12, 2026.
- Bonus structure includes mid-year performance reviews with up to 25% payout in Q3 2026 and up to 75% based on full-year results in Q1 2027.
- Performance metrics are tied to BACKBEAT (Bradycardia Marker) and Virtue SAB (Sirolimus AngioInfusion Balloon) pivotal study enrollment targets.
- CEO Hochman received a 4% base salary increase and target bonus increased from 80% to 100% of base salary.
- President/COO Sherman received a 10% base salary increase and target bonus increased from 80% to 90% of base salary.
- Revised RSU vesting schedule: four equal installments at 18, 24, 30, and 36 months.
Orchestra BioMed Holdings, Inc. announced a significant asset acquisition involving the receipt of up to $21 million in proceeds from Haemonetics' acquisition of Vivasure.
📋 Key Facts
- The company will receive up to $21 million in proceeds related to the acquisition of Vivasure by Haemonetics.
- Announcement date: January 12, 2026.
- The filing includes a press release (Exhibit 99.1) detailing the transaction.
Orchestra BioMed Holdings entered into a new $100 million 'at-the-market' (ATM) sales agreement with TD Securities (USA) LLC. Simultaneously, the company terminated its existing $100 million sales agreement with Jefferies LLC to resolve research dissemination restrictions.
🚩 Red Flags
- Significant potential for equity dilution via the new $100M ATM offering.
- Frequent changes in sales agents/agreements (transitioning from Jefferies to TD Securities).
📋 Key Facts
- Entered into a Sales Agreement with TD Securities (USA) LLC on August 12, 2024.
- The new offering allows for the sale of common stock up to an aggregate price of $100,000,000 via 'at the market' methods.
- Terminated a prior Open Market Sale Agreement with Jefferies LLC dated May 15, 2024.
- Under the terminated Jefferies agreement, $15.5 million in shares had already been sold, leaving $84.5 million remaining.
- The termination of the Jefferies agreement was intended to eliminate SEC-related restrictions on research reports being published by Jefferies.
Orchestra BioMed Holdings, Inc. announced the appointment of John Mack to its Board of Directors and Audit Committee, effective July 29, 2024. This appointment increases the size of the Board from seven to eight directors.
📋 Key Facts
- John Mack appointed as Class I director, effective July 29, 2024.
- Mr. Mack also appointed to the Company's Audit Committee.
- Board size increased from seven to eight directors.
- Mr. Mack previously served as President of Cardiac Surgery for Medtronic, Inc. (retired Jan 2023).
- Compensation will follow the Director Compensation Policy outlined in the 2023 Form 10-K.
Orchestra BioMed Holdings, Inc. held its 2024 Annual Meeting of Stockholders on June 20, 2024. The meeting resulted in the successful election of two Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- Total shares entitled to vote: 35,786,497; Total shares represented at meeting: 28,647,942.
- Election of Class I Directors: Eric A. Rose, M.D. and Jason Aryeh were both elected to serve until the 2027 annual meeting.
- Ratification of Auditor: Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Orchestra BioMed Holdings, Inc. filed an 8-K to provide a copy of a slide presentation used at investor and industry conferences as part of its Regulation FD disclosure.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains an Investor Presentation.
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Orchestra BioMed Holdings, Inc. announced the scheduling of its first Annual Meeting of Stockholders for June 20, 2024. The filing outlines record dates and deadlines for shareholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: Thursday, June 20, 2024.
- Record Date for stockholders: April 26, 2024.
- Deadline for Rule 14a-8 shareholder proposals: April 8, 2024.
- Deadline for director nominations/other business per Bylaws: April 8, 2024.
Orchestra BioMed Holdings, Inc. filed an 8-K to provide a copy of its investor presentation used at conferences and presentations via Item 7.01.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- An investor presentation was attached as Exhibit 99.1.
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liabilities.